News | Mammography | June 30, 2017

Nation’s largest independent provider of breast screening services recognized for improving technology, leading to fewer recalls and higher retention rates

Solis Mammography Ranks No. 19 in Dallas Business Journal’s Middle Market 50

June 30, 2017 — Solis Mammography was named the 19th fastest-growing, middle-market company in North Texas by the Dallas Business Journal. Rankings of the publication’s third annual research project were based on both private and public companies with revenue between $25 million and $750 million. Fifty-three companies that met the annual revenue requirements in the 2017 Middle Market 50 were awarded at the 2017 Middle Market 50 Awards Dinner at the Ritz Carlton in Dallas.

Headquartered in Addison, Texas, Solis currently operates 37 centers across six major markets – North Texas; Houston, Texas; Phoenix, Ariz.; Columbus, Ohio; Greensboro, N.C.; and, through its acquisition of Washington Radiology, the D.C. metropolitan area. The company operates both wholly-owned centers and multiple joint ventures with hospital partners. Solis Mammography (including Washington Radiology) serves more than 600,000 patients each year with highly-specialized breast imaging services including screening and diagnostic mammography (2-D and 3-D), computer-aided detection, breast ultrasound, stereotactic biopsy and ultrasound-guided biopsy.

Over the past three years, the company has committed $16 million to upgrade all of its centers with 3-D mammography (also known as digital breast tomosynthesis), lowering unnecessary recalls by 37 percent and increasing cancer detection by 54 percent. Taken together, these changes have earned the company a 76 percent annual retention rate with returning patients, far higher than the national average of 53 percent.

Under the leadership of James Polfreman, the company has more than doubled its footprint since he joined the company in 2011, increasing revenue by more than 250 percent and creating a fivefold increase in bottom line, earnings before interest, tax, depreciation and amortization (EBITDA).

For more information: www.solismammo.com


Additional Content

News | Women's Health

Oct. 29, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive ...

Time October 30, 2026
arrow
News | Radiopharmaceuticals and Tracers

Oct. 19, 2026 — Nuclidium AG, a clinical-stage radiopharmaceutical company, and NorthStar Medical Technologies, a global ...

Time October 19, 2026
arrow
News | Women's Health

Oct. 15, 2026— SimBioSys has announced U.S. Food and Drug Administration (FDA) 510(k) clearance of TumorSight Risk, its ...

Time October 19, 2026
arrow
News | Breast Imaging

Oct. 6, 2026 — The American College of Radiology (ACR) has recognized Mercy Medical Center’s Tyanna O’Brien Center for ...

Time October 09, 2026
arrow
News | Ultrasound Women's Health

Sept. 29, 2026 — A research team at the University of Virginia (UVA) led by Timothy Bullock, PhD, has published results ...

Time September 30, 2026
arrow
Subscribe Now